Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B

End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure strategiesEnd-of-treatment data from ENHANCE did not demonstrate improved HBsAg loss rates compared…

Read the full release →

News provided by PR Newswire.